氯喹和羟氯喹在SARS-Cov-2中的作用。重新利用旧药来对付今天的致命疾病

Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao
{"title":"氯喹和羟氯喹在SARS-Cov-2中的作用。重新利用旧药来对付今天的致命疾病","authors":"Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao","doi":"10.18231/j.jpbs.2020.001","DOIUrl":null,"url":null,"abstract":"Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19.\nMaterials and Methods: Here we present the database of trials with these compounds in COVID-19.\nDiscussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors.\nConclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable.\n\nKeywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome","PeriodicalId":21014,"journal":{"name":"Research journal of pharmaceutical, biological and chemical sciences","volume":"25 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Chloroquine and Hydroxychloroquine in SARS-Cov-2. Repurposing the old drugs against today’s deadly disease\",\"authors\":\"Kavita M. Jaiswal, S. Dudhgaonkar, Latesh B. Raghute, Mahek S. Kewalramani, Lohit S. Vaishnao\",\"doi\":\"10.18231/j.jpbs.2020.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19.\\nMaterials and Methods: Here we present the database of trials with these compounds in COVID-19.\\nDiscussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors.\\nConclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable.\\n\\nKeywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome\",\"PeriodicalId\":21014,\"journal\":{\"name\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"volume\":\"25 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-08-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Research journal of pharmaceutical, biological and chemical sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.jpbs.2020.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research journal of pharmaceutical, biological and chemical sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.jpbs.2020.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

摘要

简介:氯喹(CQ)和羟氯喹(HCQ)作为COVID-19的可能治疗药物获得了巨大的发展势头。在印度,该药被批准用于治疗疑似或确诊COVID-19病例的无症状卫生工作者以及确诊患者的无症状家庭接触者的预防。美国食品药品监督管理局(FDA)发布了用于治疗COVID-19的HCQ紧急使用授权(EUA)。材料和方法:在这里,我们展示了这些化合物在COVID-19中的试验数据库。讨论:中国早期注册的15例CQ和HCQ在COVID -19阳性患者中的临床试验表明,药物在抑制肺炎加重、改善肺部影像学表现、促进病毒阴性转化、缩短病程方面优于对照治疗。一些研究没有取得积极结果,包括2020年5月22日在线发表在《柳叶刀》上的一项关于使用或不使用大环内酯类药物治疗COVID-19的HCQ多国注册分析。研究表明,使用HCQ治疗COVID-19时,住院生存率降低,室性心律失常频率增加。鉴于这一出版物,世卫组织于2020年5月26日暂停了“团结”全球临床试验中的HCQ部分,HCQ /CQ治疗COVID的试验也暂停了。《柳叶刀》上的论文一直存在争议,直到2020年6月4日,这篇文章才被作者撤回。结论:在我们获得世卫组织快速通道“团结”临床试验和其他重新利用这些药物的随机临床试验的结果之前,仍然值得怀疑。关键词:covid -19大流行,冠状病毒“团结”试验,严重急性呼吸综合征
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Chloroquine and Hydroxychloroquine in SARS-Cov-2. Repurposing the old drugs against today’s deadly disease
Introduction: Chloroquine (CQ) and Hydroxychloroquine (HCQ) has received huge momentum as possible treatment for COVID-19. In India the drug is approved for prophylaxis of asymptomatic health workers treating suspected or confirmed COVID-19 cases, and asymptomatic household contacts of confirmed patients. The U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) of HCQ to treat COVID-19. Materials and Methods: Here we present the database of trials with these compounds in COVID-19. Discussion: Early 15 registered clinical trials of CQ and HCQ in COVID -19 positive patients in China, showed that the drugs were superior to the control treatment in inhibiting the exacerbation of pneumonia, improving lung imaging findings, promoting a virus-negative conversion, and shortening the disease course. Some studies had no positive results including a multinational registry analysis of HCQ with or without a macrolide for treatment of COVID-19 published online in Lancet on 22nd May 2020.The study showed that there was decreased in-hospital survival and an increased frequency of ventricular arrhythmias when HCQ was used for treatment of COVID-19.In the light of this publication the WHO temporarily paused the HCQ arm of its ‘Solidarity’ global clinical trial on 26th May 2020 and trials with HCQ /CQ for COVID were also suspended. The Lancet paper was in controversy until finally on June 4th 2020 the article was retracted by authors. Conclusions: Until we get results of WHO fast track ‘Solidarity’ clinical trial and other randomized clinical trials repurposing these drugs remains questionable. Keywords: CQVID-19 pandemic, Corona ‘Solidarity’ trial, Severe acute respiratory syndrome
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Novel therapeutic delivery for neurodegenerative diseases: Strategies to overcome CNS barriers Drug repurposing: A futuristic approach in drug discovery A review on ebola virus Evaluation and clinical management of drug-drug interactions in hypertensive patients associated co-morbidities: A study in general medicine and ICU ward Recent advances in nanotherapeutics for epilepsy and neurodegenerative diseases
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1